An Eastern Cooperative Oncology Group phase II study of single agent DHAD, VP-16, aclacinomycin, or spirogermanium in metastatic pancreatic cancer.
There were 80 patients with measurable metastatic or unresectable pancreatic cancer randomly assigned to treatment with either DHAD, VP-16, aclacinomycin, or spirogermanium. There were no complete or partial responses. Two deaths from leukopenia occurred in patients treated with DHAD. One patient receiving spirogermanium experienced a seizure. No other life-threatening toxicities occurred. Maximal toxicities were not significantly more frequent with any treatment group. Median survival was 10 weeks, and median time to progression was only 6 weeks, with no difference among these four therapies.
Asbury
R F
RF
Genesee Hospital, University of Rochester Cancer Center, New York 14607.
Cnaan
A
A
Johnson
L
L
Harris
J
J
Zaentz
S D
SD
Haller
D G
DG
D015250:Aclarubicin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005047:Etoposide / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008942:Mitoxantrone / Q000009:adverse effects / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000009:adverse effects / Q000627:therapeutic use; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D013141:Spiro Compounds / Q000009:adverse effects / Q000627:therapeutic use; D015996:Survival Rate
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D009942:Organometallic Compounds; D013141:Spiro Compounds; C011157:aclacinomycins; C026818:spirogermanium; D005047:Etoposide; D015250:Aclarubicin; D008942:Mitoxantrone